Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected iranian population

Genes and Immunity

Volumn 16, Issue 8, 2015, Pages 514-518

  Carapito, R ^a   Poustchi, H ^b   Kwemou, M ^a   Untrau, M ^a   Sharifi, A H ^b   Merat, S ^b,c   Haj Sheykholeslami, A ^b   Jabbari, H ^b   Esmaili, S ^b   Michel, S ^a   Toussaint, J ^a   Le Gentil, M ^a   Ansari Moghaddam, A ^d   Radosavljevic, M ^a   Etemadi, A ^b,e   Georgel, P ^a   Malekzadeh, R ^b,c   Bahram, S ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 28B; EGFR PROTEIN, HUMAN; GENETIC MARKER; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; FEMALE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; IRANIAN PEOPLE; MAJOR CLINICAL STUDY; MALE; PATHOGEN CLEARANCE; PERSISTENT VIRUS INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; GENETIC MARKER; GENETICS; HEPACIVIRUS; IMMUNOLOGY; IRAN; MULTIVARIATE ANALYSIS; PHYSIOLOGY; REMISSION;

GENETIC MARKERS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; IRAN; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION, SPONTANEOUS;

EID: 84949110441     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2015.38     Document Type: Article

References (27)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
2. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
3. Merat S, Poustchi H. Hepatitis C in Iran. How extensive of a problem is it? Arch Iran Med 2012; 15: 268.
4. Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG et al. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One 2011; 6: e23830.
5. Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009; 10: 1819-1837.
6. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis 2008; 12: 713-726; xi.
7. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immunity 2004; 5: 237-245.
8. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-874.
9. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immunity 2003; 4: 411-419.
10. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171.
11. Mosbruger TL, Duggal P, Goedert JJ, Kirk GD, Hoots WK, Tobler LH et al. Largescale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010; 201: 1371-1380.
12. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
13. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592 e1.
14. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
15. Rao HY, Sun DG, Yang RF, Liu F, Wang J, Feng B et al. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. J Gastroenterol Hepatol 2012; 27: 526-532.
16. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007; 196: 1474-1482.
17. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59: 109-120.
18. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129 e18.
19. Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 2012; 7: e37054.
20. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116.
21. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15: 72-79.
22. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460-466.
23. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595.
24. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849.
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
26. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR et al. Cohort Profile: The Golestan Cohort Study-a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol 2010; 39: 52-59.
27. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.